laitimes

Hengrui Pharmaceutical: Famitinib malate capsules and carellizumab for injection were approved for clinical trials

Xu Jinzhong, trainee reporter Ni Ming, China Securities News, China Securities Network

On the evening of October 22, Hengrui Pharmaceutical announced that the company and its subsidiary Suzhou Shengdia Biopharmaceutical Co., Ltd. recently received the approval of the State Drug Administration to issue a "Drug Clinical Trial Approval Notice" on famitinib malate capsules and carrelizumab for injection, and will carry out clinical trials in the near future.

The announcement said that as of now, the cumulative research and development costs of carelliltuzumab-related projects for injection have been about 1.73 billion yuan. The cumulative investment in research and development costs of famitinib-related projects in malate is about 170 million yuan.

Read on